机译:IL-10受体β的多态性影响用沙利度胺和/或硼替佐米治疗的多发性骨髓瘤患者的预后
Department of Laboratory SciencesGunma University Graduate School of Health SciencesMaebashi Gunma;
Department of Laboratory SciencesGunma University Graduate School of Health SciencesMaebashi Gunma;
Department of Laboratory SciencesGunma University Graduate School of Health SciencesMaebashi Gunma;
Department of Laboratory SciencesGunma University Graduate School of Health SciencesMaebashi Gunma;
Department of Medicine and Clinical ScienceGunma UniversityMaebashi Gunma Japan;
Department of Medicine and Clinical ScienceGunma UniversityMaebashi Gunma Japan;
National Hospital OrganizationNishigunma National HospitalShibukawa Gunma Japan;
National Hospital OrganizationNishigunma National HospitalShibukawa Gunma Japan;
Blood Transfusion ServiceGunma University HospitalMaebashi Gunma Japan;
Department of Medicine and Clinical ScienceGunma UniversityMaebashi Gunma Japan;
Oncology CenterGunma University HospitalMaebashi Gunma Japan;
Department of Laboratory SciencesGunma University Graduate School of Health SciencesMaebashi Gunma;
bortezomib; interleukin‐10 receptor; multiple myeloma; polymorphism; thalidomide;
机译:IL-10受体β的多态性影响用沙利度胺和/或硼替佐米治疗的多发性骨髓瘤患者的预后
机译:IL1B基因启动子区域中的单核苷酸多态性影响接受大剂量化疗的多发性骨髓瘤患者的预后,与沙利度胺和硼替佐米的复发治疗无关。
机译:IL1B基因启动子区域的单核苷酸多态性影响接受大剂量化疗的多发性骨髓瘤患者的结局,与沙利度胺和硼替佐米的复发治疗无关
机译:TGF-β1和-1082G / A SNP的信号肽的多态性频率在颈动脉狭窄患者IL-10基因启动子区的促进区
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:CYP2C19和CYP2D6多态性对多发性骨髓瘤患者环磷酰胺沙利度胺和硼替佐米的疗效无影响
机译:IL1B基因启动子区域的单核苷酸多态性影响接受大剂量化疗的多发性骨髓瘤患者的结局,与沙利度胺和硼替佐米的复发治疗无关